This site is intended for healthcare professionals
News

FDA grants priority review for NDA for Oleogel-S10 to treat Epidermolysis Bullosa.- Amryt

Read time: 1 mins
Last updated:3rd Jun 2021
Published:4th Jun 2021
Amryt announces that the FDA has granted Priority Review for Amryt’s New Drug Application (“NDA”) for Oleogel-S10 for the treatment of Epidermolysis Bullosa (“EB”). Oleogel-S10 is a potential treatment for the cutaneous manifestations of Junctional and Dystrophic EB, a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment.
Condition: Epidermolysis Bullosa
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest